|1.||Loebel, Antony: 28 articles (01/2016 - 06/2009)|
|2.||Cucchiaro, Josephine: 21 articles (01/2016 - 06/2009)|
|3.||Pikalov, Andrei: 13 articles (01/2016 - 09/2011)|
|4.||Citrome, Leslie: 13 articles (01/2015 - 01/2011)|
|5.||Ogasa, Masaaki: 7 articles (08/2015 - 06/2009)|
|6.||Hsu, Jay: 7 articles (08/2014 - 02/2013)|
|7.||Silva, Robert: 6 articles (12/2015 - 09/2011)|
|8.||Rajagopalan, Krithika: 6 articles (11/2015 - 01/2013)|
|9.||Harvey, Philip D: 6 articles (08/2015 - 02/2011)|
|10.||Phillips, Debra: 5 articles (01/2016 - 06/2009)|
|1.||Schizophrenia (Dementia Praecox)
06/01/2014 - "To address this point, we treated rats during adolescence with the multi-receptor antipsychotic lurasidone, which was proven to be effective in animal models of schizophrenia. "
04/01/2015 - "In a pooled analysis of short-term, placebo-controlled studies, lurasidone significantly improved depressive symptoms in patients with schizophrenia."
01/01/2015 - "In this pooled analysis of short-term studies in patients with acute schizophrenia, lurasidone demonstrated significant improvement for each of the five PANSS factor scores, indicating effectiveness across the spectrum of schizophrenia symptoms."
02/01/2013 - "In this study, which was limited by a relatively high discontinuation rate, lurasidone provided effective treatment for patients with acute exacerbation of chronic schizophrenia and had minimal effects on weight and metabolic parameters."
01/01/2012 - "Short-term clinical trials have demonstrated the efficacy of lurasidone in acute schizophrenia, with doses of 40 and 80 mg/day giving significant improvements from baseline in the PANSS and BPRS scores. "
|2.||Bipolar Disorder (Mania)
01/01/2015 - "Lurasidone: a new treatment option for bipolar depression-a review."
11/01/2015 - "In this post-hoc analysis, rates of remission and recovery were evaluated in patients with bipolar depression treated with lurasidone. "
02/01/2016 - "An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder."
11/01/2015 - "Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study."
04/01/2015 - "Lurasidone was found in this post hoc analysis to be efficacious in the treatment of patients with bipolar depression who present with mixed features (assessed cross-sectionally at study baseline). "
02/01/2014 - "Lurasidone was not associated with any clinically meaningful mean weight or metabolic changes compared to placebo; NNH vs. placebo for weight gain ≥7% was 29 for 20-60mg/d and 5550 for 80-120mg/d and 42 for adjunctive lurasidone. "
12/01/2013 - "The minimal propensity for weight gain as well as the metabolic neutrality of lurasidone in the bipolar population is a clinically significant advantage. "
05/01/2013 - "Weight gain ≥ 7% occurred in 8.2% of patients receiving lurasidone and 3.2% receiving placebo. "
04/01/2013 - "The proportion of patients experiencing ≥ 7% weight gain was 4% for each lurasidone group, 15% for the QXR-600 mg group, and 3% for the placebo group. "
07/01/2012 - "Advantages for lurasidone include a low propensity for weight gain and metabolic abnormalities. "
|4.||Psychotic Disorders (Schizoaffective Disorder)
08/01/2014 - "Patients in this multicenter, 6-month open-label, flexible-dose, extension study had completed a core 6-week randomized trial in which clinically stable, but symptomatic, outpatients with schizophrenia or schizoaffective disorder were switched to lurasidone. "
04/01/2014 - "This study examined D2 receptor occupancy and its association with clinical improvement and side effects in patients with schizophrenia or schizoaffective disorder following repeated doses of 80, 120, or 160 mg/day of lurasidone. "
02/01/2013 - "Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2 weeks of the study: (1) 40 mg/d for 2 weeks; (2) 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2 (up-titration group); and (3) 80 mg/d for 2 weeks. "
08/01/2014 - "To evaluate the long-term safety and tolerability of lurasidone in schizophrenia and schizoaffective disorder patients switched to lurasidone. "
04/01/2014 - "(DSM-IV) diagnoses of schizophrenia or schizoaffective disorder were washed out of their antipsychotic medications (5 half-lives) and randomly assigned to 80, 120, or 160 mg/day of lurasidone. "
|5.||Psychomotor Agitation (Akathisia)
03/01/2012 - "Higher doses do not appear to be more efficacious, and may be associated with increases in adverse effects, such as somnolence and akathisia; however, this tolerability issue was not observed in one recently conducted 6-week study when lurasidone was administered at a dose of 160 mg/day. "
01/01/2015 - "Data showed that the relative risk (RR) of akathisia was double that of controls, with lurasidone having the highest individual RR at 2.7 [CI: 2-3.6]. "
01/01/2015 - "Lurasidone was well- tolerated, and commonly observed adverse reactions (incidence ≥5% and at least twice the rate for placebo) were akathisia, extrapyramidal symptoms, and somnolence. "
05/01/2013 - "Akathisia was the most commonly reported adverse event with lurasidone (17.6%, versus 3.1% with placebo). "
11/01/2011 - "The incidence of extrapyramidal symptoms (excluding akathisia/restlessness) was greater with lurasidone (14.7%) than placebo (5.1%). "
|2.||Antipsychotic Agents (Antipsychotics)
|7.||olanzapine-fluoxetine combination (Symbyax)
|10.||serotonin 7 receptor
|2.||Drug Therapy (Chemotherapy)